Advertisement
YOU ARE HERE: LAT HomeCollectionsSelzentry Drug
IN THE NEWS

Selzentry Drug

FEATURED ARTICLES
SCIENCE
August 7, 2007 | Jia-Rui Chong, Times Staff Writer
Providing a new alternative to AIDS patients who have developed resistance to multiple drugs, the Food and Drug Administration on Monday approved the first-ever pill that works by defending human immune cells instead of attacking the deadly virus. The drug, which will be sold in the United States under the trade name Selzentry, prevents the AIDS virus from entering immune cells by clogging up a cell receptor known as CCR5. All previous drugs have targeted parts of the virus.
ARTICLES BY DATE
SCIENCE
August 7, 2007 | Jia-Rui Chong, Times Staff Writer
Providing a new alternative to AIDS patients who have developed resistance to multiple drugs, the Food and Drug Administration on Monday approved the first-ever pill that works by defending human immune cells instead of attacking the deadly virus. The drug, which will be sold in the United States under the trade name Selzentry, prevents the AIDS virus from entering immune cells by clogging up a cell receptor known as CCR5. All previous drugs have targeted parts of the virus.
Advertisement
SCIENCE
September 6, 2007 | Jia-Rui Chong, Times Staff Writer
A federal advisory panel on Wednesday unanimously recommended accelerated approval for a new AIDS drug designed to treat the increasing number of patients with drug-resistant strains of the virus. Isentress, developed by Merck & Co., is the first in a class known as integrase inhibitors, which prevent HIV from merging into the DNA of human cells. The panel's recommendation follows the approval last month of Pfizer Inc.'s Selzentry.
Los Angeles Times Articles
|